InterContinental Beverage Capital has partnered with nutrition and biotechnology company PanTheryx to expand Relesium, a patented natural supplement easing digestive side effects from GLP-1 medications. Together, they will refine commercial strategies, develop new product formats, and secure strategic beverage and consumer packaged goods growth partners.
-- InterContinental Beverage Capital (IBC), a global advisory firm specializing in the beverage and consumer packaged goods industries, today announced a partnership with nutrition and biotechnology company PanTheryx to lead the commercial expansion of Relesium®. Relesium is a patented, all-natural supplement designed to address digestive side effects associated with GLP-1 medications. Under the partnership, IBC will collaborate with PanTheryx leadership on go-to-market strategy, explore new product formats built on Relesium’s intellectual property and identify strategic beverage and CPG partners.
Formulated with antibody-rich chicken egg powder and bovine colostrum, Relesium’s underlying science is supported by peer-reviewed research published in Nutrients, written by Raymond Playford, M.D., Ph.D., (PanTheryx’s Medical Director), alongside observational pilot study research led Harry Oken, M.D. (University of Maryland) and Michael Roizen, M.D. (Cleveland Clinic).
“PanTheryx has built something rare in Relesium: a patented, science-backed product aimed at one of the fastest-growing consumer health audiences in the world,” says Joseph Messina, President and Managing Partner at IBC. “Our team is excited to bring our network of brand, channel and partnership resources to Relesium as it scales across new categories and markets.”
“Millions of people are now taking GLP-1 medications, and many are looking for a natural way to manage digestive discomfort,” says Tom Feeley, President and CEO of PanTheryx. “IBC brings deep consumer and beverage expertise and a strategic network that will help us reach more of those consumers, in more formats and through more channels.”
About PanTheryx
PanTheryx® is a nutrition and biotechnology company headquartered in Boulder, Colorado. It develops science-based, naturally derived solutions for digestive and immune health. Its portfolio includes Relesium®, a patented supplement formulated for GLP-1 medication users, as well as DiaResQ and Life’s First Naturals. https://pantheryx.com.
About InterContinental Beverage Capital, Inc.
IBC is a global advisory firm focused on the beverage and consumer packaged goods industries. IBC has a strategic network of industry relationships worldwide, investment capital resources, and institutional debt sources, along with specialized consultants and management teams. These resources provide partner companies with expertise, industry proficiencies and access to new markets with supply chain and R&D resources, and investment and commercial banking capabilities. IBC is actively seeking companies in targeted verticals with unique products and dedicated management that can develop into category leaders. https://www.inbevcapital.com.
Contact Info:
Name: Leah Messina
Email: Send Email
Organization: Sinuate Media
Address: 119 Pondfield Rd. #174 Bronxville, NY 10708
Phone: 917-843-8164
Website: https://www.sinuatemedia.com
Release ID: 89205027
If you come across any problems, discrepancies, or concerns related to the content contained within this press release that necessitate action or if a press release requires takedown, we strongly encourage you to reach out without delay by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will be readily accessible round-the-clock to address your concerns within 8 hours and take appropriate actions to rectify identified issues or support with press release removals. Ensuring accurate and reliable information remains our unwavering commitment.
